0000000000498647

AUTHOR

Martina Di Pietro

showing 5 related works from this author

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Fetal variant of posterior cerebral artery: just a physiologic variant or a window for possible ischemic stroke?

2021

N/A

medicine.medical_specialtyNeurologyDermatologyPosterior cerebral arteryBrain IschemiaText miningmedicine.arteryInternal medicinemedicineHumansNeuroradiologyIschemic StrokePosterior Cerebral ArteryFetusbusiness.industryWindow (computing)Settore MED/37 - NeuroradiologiaGeneral MedicineCerebral AngiographyStrokePsychiatry and Mental healthIschemic strokeCardiologySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness
researchProduct

Clinical pharmacology of citrus aurantium and citrus sinensis for the treatment of anxiety

2018

Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects ofCitrus aurantiumorCitrus sinensisessential oils (EOs).Design. The bibliographic research was made on the major scientific databases. Analysis included only articles written in English and published on peer-reviewed scientific journals describing preclinical experiments and clinical trials carried out to investigate the antianxiety effects ofCitrus aurantium or Citrus sinensisEOs on anxiety disorders. Clinical studies reporting the antianxiety effects of products containingCitrus aurantiumorCitrus sinensisEOs in combination with other active substances, including medicinal pla…

medicine.drug_classAnxietyAnxiolyticlaw.invention03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegalelawmedicineCitrus aurantium; Citrus sinensis; Anxiety; Complementary and Alternative Medicine030212 general & internal medicineMedicinal plantsCitrus aurantiumClinical pharmacologyTraditional medicinebusiness.industryPharmacology Citrus aurantium Citrus sinensis Anxietyfood and beverageslcsh:Other systems of medicinelcsh:RZ201-999Clinical trialComplementary and alternative medicineAnxiogenicAnxietymedicine.symptombusiness030217 neurology & neurosurgeryCitrus × sinensisCitrus sinensisAromatherapy
researchProduct

A Critical Review of Alien Limb-Related Phenomena and Implications for Functional Magnetic Resonance Imaging Studies

2021

Consensus criteria on corticobasal degeneration (CBD) include alien limb (AL) phenomena. However, the gist of the behavioral features of AL is still “a matter of debate.” CBD-related AL has so far included the description of involuntary movements, frontal release phenomena (frontal AL), or asomatognosia (posterior or “real” AL). In this context, the most frequent symptoms are language and praxis deficits and cortical sensory misperception. However, asomatognosia requires, by definition, intact perception and cognition. Thus, to make a proper diagnosis of AL in the context of CBD, cognitive and language dysfunctions must be carefully verified and objectively assessed. We reviewed the current…

media_common.quotation_subjectContext (language use)ReviewAsomatognosiaPerceptionmedicineCorticobasal degenerationUtilization behaviorSet (psychology)RC346-429alien limbmedia_commondiagonistic dyspraxiamedicine.diagnostic_testneurodegenerationCognitioncorticobasal syndromemedicine.diseaseNeurologyalien handSettore MED/26 - NeurologiaNeurology (clinical)Neurology. Diseases of the nervous systemFunctional magnetic resonance imagingPsychologyCognitive psychologyFrontiers in Neurology
researchProduct

A Stage-Based Approach to Therapy in Parkinson’s Disease

2019

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-phar…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseImpulse control disorderlcsh:QR1-502ReviewDiseasel-dopaBiochemistryREM sleep behavior disorderMotor symptomslcsh:MicrobiologyAntiparkinson Agentsnon-pharmacological therapy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansdopamine-agonistsApathyanticholinergicsResting tremorMolecular Biologyamantadinebusiness.industryAmantadineParkinson Diseasemonoamine oxidase inhibitorsmotor symptomsmedicine.diseasenon-motor symptoms030104 developmental biologyacetylcholinesterase inhibitorsParkinson’s disease<span style="font-variant: small-caps">l</span>-dopaSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugBiomolecules
researchProduct